A comprehensive manually curated reaction map of RANKL/RANK-signaling pathway
暂无分享,去创建一个
Gary D. Bader | Gary D Bader | Akhilesh Pandey | S. Sujatha Mohan | Rajesh Raju | T. S. Keshava Prasad | Jyoti Sharma | Lavanya Balakrishnan | Mitali Bhattacharjee | B. Abdul Rahiman | Derese Getnet | Babylakshmi Muthusamy | Vishalakshi Nanjappa | Joji Kurian Thomas | Subramanian Shankar | H. C. Harsha | Mohan R. Wani | A. Pandey | S. Mohan | D. Getnet | J. K. Thomas | Babylakshmi Muthusamy | Lavanya Balakrishnan | Vishalakshi Nanjappa | Rajesh Raju | Jyoti Sharma | S. Shankar | B. A. Rahiman | T. K. Prasad | H. Harsha | M. Bhattacharjee | M. Wani | Mitali Bhattacharjee | A. Pandey | A. Pandey
[1] Gary D Bader,et al. BioPAX – A community standard for pathway data sharing , 2010, Nature Biotechnology.
[2] R. Owens,et al. Structural and Functional Insights of RANKL–RANK Interaction and Signaling , 2010, The Journal of Immunology.
[3] Ugur Dogrusoz,et al. VISIBIOweb: visualization and layout services for BioPAX pathway models , 2010, Nucleic Acids Res..
[4] Chris Sander,et al. ChiBE: interactive visualization and manipulation of BioPAX pathway models , 2010, Bioinform..
[5] Sandra E. Orchard,et al. Molecular Interactions and Data Standardisation , 2010, Proteome Bioinformatics.
[6] Gary D Bader,et al. NetPath: a public resource of curated signal transduction pathways , 2010, Genome Biology.
[7] Y. Abu-Amer,et al. Impediment of NEMO oligomerization inhibits osteoclastogenesis and osteolysis , 2009, Journal of cellular biochemistry.
[8] A. Haeseler,et al. Central control of fever and female body temperature by RANKL/RANK , 2009, Nature.
[9] Kumaran Kandasamy,et al. PathBuilder - open source software for annotating and developing pathway resources , 2009, Bioinform..
[10] R. Cole,et al. Identification of c‐Src tyrosine kinase substrates in platelet‐derived growth factor receptor signaling , 2009, Molecular oncology.
[11] Chris T. Evelo,et al. Community curation on WikiPathways: How we assist knowledge collection , 2009 .
[12] J. Pelletier,et al. New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target? , 2009, The Keio journal of medicine.
[13] M. J. Marshall,et al. RANK, RANKL and osteoprotegerin in bone biology and disease , 2009, Current reviews in musculoskeletal medicine.
[14] O. Dittrich‐Breiholz,et al. A comprehensive map of the IL-1R signalling network , 2009, Cell Communication and Signaling.
[15] R. Faccio,et al. The Src family kinase, Lyn, suppresses osteoclastogenesis in vitro and in vivo , 2009, Proceedings of the National Academy of Sciences.
[16] E. Montgomery,et al. Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers , 2009, Cancer biology & therapy.
[17] Chris Mungall,et al. AmiGO: online access to ontology and annotation data , 2008, Bioinform..
[18] Sandhya Rani,et al. Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..
[19] S. Teitelbaum,et al. Tumor Necrosis Factor Receptor-associated Factor 6 Is an Intranuclear Transcriptional Coactivator in Osteoclasts* , 2008, Journal of Biological Chemistry.
[20] R. Faccio,et al. RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. , 2008, The Journal of clinical investigation.
[21] T. Yoneda,et al. JNK/c‐Jun Signaling Mediates an Anti‐Apoptotic Effect of RANKL in Osteoclasts , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[22] Shao-Cong Sun,et al. Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. , 2008, The Journal of clinical investigation.
[23] W. Zou,et al. RelB is the NF-κB subunit downstream of NIK responsible for osteoclast differentiation , 2008, Proceedings of the National Academy of Sciences.
[24] W. Alexander,et al. A Novel Mutation in the Nfkb2 Gene Generates an NF-κB2 “Super Repressor”1 , 2007, The Journal of Immunology.
[25] N. Bishop,et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL , 2007, Nature Genetics.
[26] E. Wagner,et al. NF-κB p50 and p52 Regulate Receptor Activator of NF-κB Ligand (RANKL) and Tumor Necrosis Factor-induced Osteoclast Precursor Differentiation by Activating c-Fos and NFATc1* , 2007, Journal of Biological Chemistry.
[27] J. Penninger,et al. RANK signals from CD4+3− inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla , 2007, The Journal of Experimental Medicine.
[28] W. Alexander,et al. A novel mutation in the Nfkb2 gene generates an NF-kappa B2 "super repressor". , 2007, Journal of immunology.
[29] Alexander R. Pico,et al. GenMAPP 2: new features and resources for pathway analysis , 2007, BMC Bioinformatics.
[30] Ron Bose,et al. Phosphoproteomic analysis of Her2/neu signaling and inhibition. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[31] H. Kitano,et al. A comprehensive map of the toll-like receptor signaling network , 2006, Molecular systems biology.
[32] J. Penninger,et al. Receptor Activator of NF-κB Ligand Regulates the Proliferation of Mammary Epithelial Cells via Id2 , 2006, Molecular and Cellular Biology.
[33] Y. Kadono,et al. Identification of an Alternatively Spliced Variant of Ca2+-promoted Ras Inactivator as a Possible Regulator of RANKL Shedding* , 2005, Journal of Biological Chemistry.
[34] Osami Kanagawa,et al. NF-κB–inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis , 2005 .
[35] H. Kitano,et al. A comprehensive pathway map of epidermal growth factor receptor signaling , 2005, Molecular systems biology.
[36] Georg Schett,et al. IκB kinase (IKK)β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss , 2005, The Journal of experimental medicine.
[37] H. Kitaura,et al. NF-(kappa)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. , 2005, The Journal of clinical investigation.
[38] S. Akira,et al. Osteoclast Differentiation Is Impaired in the Absence of Inhibitor of κB Kinase α* , 2004, Journal of Biological Chemistry.
[39] C. Sander,et al. The HUPO PSI's Molecular Interaction format—a community standard for the representation of protein interaction data , 2004, Nature Biotechnology.
[40] S. Akira,et al. Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha. , 2004, The Journal of biological chemistry.
[41] Sakae Tanaka,et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. , 2004, The Journal of clinical investigation.
[42] D. Heymann,et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. , 2003, The American journal of pathology.
[43] P. Shannon,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.
[44] W. Lindenmaier,et al. Enhanced Effector and Memory CTL Responses Generated by Incorporation of Receptor Activator of NF-κB (RANK)/RANK Ligand Costimulatory Molecules into Dendritic Cell Immunogens Expressing a Human Tumor-Specific Antigen 12 , 2003, The Journal of Immunology.
[45] C. Blobel,et al. Catalytic Properties of ADAM19* , 2003, Journal of Biological Chemistry.
[46] Hiroaki Kitano,et al. The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models , 2003, Bioinform..
[47] M. Ostrowski,et al. Cooperation of TNF Family Members CD40 Ligand, Receptor Activator of NF-κB Ligand, and TNF-α in the Activation of Dendritic Cells and the Expansion of Viral Specific CD8+ T Cell Memory Responses in HIV-1-Infected and HIV-1-Uninfected Individuals 1 , 2003, The Journal of Immunology.
[48] E. Wagner,et al. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms , 2002, Journal of Cell Science.
[49] D. Adams,et al. Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. , 2002, Blood.
[50] S. Kumta,et al. Sensitivity to Quorn mycoprotein (Fusarium venenatum) in a mould allergic patient , 2002, Journal of Clinical Pathology.
[51] R. Kitazawa,et al. RANK ligand is a prerequisite for cancer‐associated osteolytic lesions , 2002, The Journal of pathology.
[52] Y. Kadono,et al. Possible Involvement of IκB Kinase 2 and MKK7 in Osteoclastogenesis Induced by Receptor Activator of Nuclear Factor κB Ligand , 2002 .
[53] Tadashi Hata,et al. Crystal Structure of the Extracellular Domain of Mouse RANK Ligand at 2.2-Å Resolution* , 2002, The Journal of Biological Chemistry.
[54] N. Sakurai,et al. Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. , 2002, Molecular and cellular biology.
[55] Y. Kadono,et al. Possible involvement of IkappaB kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor kappaB ligand. , 2002, Journal of Bone and Mineral Research.
[56] R. Bataille,et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. , 2001, Blood.
[57] C. Nelson,et al. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. , 2001, The Journal of clinical investigation.
[58] M. Naramura,et al. A Positive Regulatory Role for Cbl Family Proteins in Tumor Necrosis Factor-related Activation-induced Cytokine (TRANCE) and CD40L-mediated Akt Activation* , 2001, The Journal of Biological Chemistry.
[59] William Maloney,et al. Receptor Activator of NF-κB and Osteoprotegerin Expression by Human Microvascular Endothelial Cells, Regulation by Inflammatory Cytokines, and Role in Human Osteoclastogenesis* , 2001, The Journal of Biological Chemistry.
[60] L. Lum,et al. Biochemical and Pharmacological Criteria Define Two Shedding Activities for TRANCE/OPGL That Are Distinct from the Tumor Necrosis Factor α Convertase* , 2001, The Journal of Biological Chemistry.
[61] L. Hofbauer,et al. Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology , 2001, Journal of Molecular Medicine.
[62] L. Lum,et al. Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase. , 2001, The Journal of biological chemistry.
[63] M. Tsujimoto,et al. Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-κB Ligand (RANKL)* , 2000, The Journal of Biological Chemistry.
[64] D. Lacey,et al. The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland Development , 2000, Cell.
[65] E. Wagner,et al. Osteoclast lineage commitment of bone marrow precursors through expression of membrane-bound TRANCE. , 2000, Bone.
[66] H. Hanafusa,et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. , 1999, Molecular cell.
[67] T. Martin,et al. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. , 1999, Bone.
[68] L. Lum,et al. Evidence for a Role of a Tumor Necrosis Factor-α (TNF-α)-converting Enzyme-like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dendritic Cell Survival* , 1999, Journal of Biological Chemistry.
[69] L. Lum,et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. , 1999, The Journal of biological chemistry.
[70] Yongwon Choi,et al. TRANCE Is Necessary and Sufficient for Osteoblast-mediated Activation of Bone Resorption in Osteoclasts , 1998, The Journal of experimental medicine.
[71] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[72] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[73] S. Mochizuki,et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.
[74] R. Steinman,et al. TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.
[75] R. Dubose,et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.
[76] Brian R. Wong,et al. TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.
[77] G Shimamoto,et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.
[78] Allan Bradley,et al. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice , 1991, Cell.